Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Conference on the future of Type 1 Diabetes screening organized as part of the ASSET
The Leading Healthcare Foundation, part of the ASSET innovation partnership led by Diamyd Medical, organizes a conference on November 26, 2024, in Stockholm, Sweden, on Type 1 Diabetes screening and treatment, co-sponsored by Sanofi. The event features keynote lectures and panel discussions on integrating new screening technologies and precision medicine therapies into healthcare systems.
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
FDA accepts Dupixent sBLA for chronic spontaneous urticaria treatment, with pivotal data showing significant itch and hive reduction. Decision expected by April 18, 2025, potentially marking the first targeted therapy for CSU in a decade.
Press Release: Dupixent sBLA accepted for FDA review for
FDA accepts Dupixent sBLA for chronic spontaneous urticaria, with a decision expected by April 18, 2025. New data confirm Dupixent significantly reduces itch and hive activity, potentially offering the first targeted therapy for CSU in a decade.
Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial
IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody therapeutic for peanut allergy, in the ACCELERATE Peanut phase 1 clinical trial. The trial aims to assess safety, tolerability, and proof of mechanism in patients aged 15 years and older. IGNX001 attaches to peanut proteins to neutralize them, differing from other immunotherapies like Palforzia and Xolair. The trial is ongoing in Australia, with recruitment targeting older adolescents and adults, and initial results expected mid-2025.
More Than 110 Organizations Call on Congress to Reauthorize PAHPA Before End of Year
110+ organizations urge Congress to reauthorize PAHPA by Dec 31, recognizing the opportunity to strengthen national health security during the 2025 leadership transition.
Sarclisa recommended for EU approval by the CHMP to treat transplant ...
CHMP recommends EU approval of Sarclisa with VRd for transplant-ineligible NDMM, based on IMROZ phase 3 study showing improved PFS. If approved, Sarclisa would be the first anti-CD38 therapy in the EU for this combination.
Sarclisa recommended for EU approval by the
CHMP recommends EU approval of Sarclisa with VRd for transplant-ineligible NDMM, based on IMROZ phase 3 study showing improved PFS. If approved, Sarclisa would be the first anti-CD38 therapy in the EU for this use.
Sanofi, Formation and OpenAI design AI tool to slash clinical trial timelines
Sanofi, Formation Bio, and OpenAI collaborate to create Muse, an AI tool accelerating clinical trial recruitment. Muse compiles disease research, identifies ideal patient profiles, and auto-generates customized recruitment materials, aiming to reduce recruitment time to minutes.
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio reports Q3 2024 financial results, with $183M in cash, cash equivalents, and short-term investments, supporting operations into H1 2026. Clinical data from RESET-Myositis™, RESET-SLE™, and initial RESET-SSc™ trials to be presented at ACR Convergence 2024. 16 patients enrolled, 10 dosed in the RESET™ program, with 40 U.S. clinical sites actively recruiting. Plans to meet with FDA in 2025 for potential registrational program designs for CABA-201. Clinical development expands into Europe with EMA CTA authorization for CABA-201 in lupus; Gerwin Winter appointed as Senior VP and Head of International.
© Copyright 2025. All Rights Reserved by MedPath